Zhao L Q, Deng L, Cao L, Chen D M, Sun Y, Zhu R N, Wang F, Guo Q, Zhou Y T, Jia L P, Huang H, Kang X H, Jin F H, Yuan Y, Zhang N, De R, Qian Y
Laboratory of Virology, Beijing Key Laboratory of Etiology of Viral Diseases in Children, Capital Institute of Pediatrics, Beijing 100020, China.
Department of Infectious Diseases, Affiliated Children's Hospital, Capital Institute of Pediatrics, Beijing 100020, China.
Zhonghua Er Ke Za Zhi. 2020 Aug 2;58(8):635-639. doi: 10.3760/cma.j.cn112140-20200426-00437.
To investigate the spectrum of pathogenic agents in pediatric patients with acute respiratory infections (ARI) during the outbreak of coronavirus infectious diseases 2019 (COVID-19). Three groups of children were enrolled into the prospective study during January 20 to February 20, 2020 from Capital Institute of Pediatrics, including children in the exposed group with ARI and epidemiological history associated with COVID-19 from whom both pharyngeal and nasopharyngeal swabs were collected, children in the ARI group without COVID-19 associated epidemiological history and children in the screening group for hospital admission, with neither COVID-19 associated epidemiological history nor ARI. Only nasopharyngeal swabs were collected in the ARI group and screening group. Each group is expected to include at least 30 cases. All specimens were tested for 2019-nCoV nucleic acid by two diagnostic kits from different manufacturers. All nasopharyngeal swabs were tested for multiple respiratory pathogens, whilst the results from the ARI group were compared with that in the correspondence periods of 2019 and 2018 used by or χ(2) test. A total of 244 children were enrolled into three groups, including 139 males and 105 females, the age was (5±4) years. The test of 2019-nCoV nucleic acid were negative in all children, and high positive rates of pathogens were detected in exposed (69.4%, 25/36) and ARI (55.3%, 73/132) groups, with the highest positive rate for mycoplasma pneumoniae (MP) (19.4%, 7/36 and 17.4%, 23/132, respectively), followed by human metapneumovirus (hMPV) (16.7%, 6/36 and 9.8%, 13/132, respectively). The positive rate (11.8%, 9/76) of pathogens in the screening group was low. In the same period of 2019, the positive rate of pathogens was 83.7% (77/92), with the highest rates for respiratory syncytial virus (RSV) A (29.3%, 27/92), followed by influenza virus (Flu) A (H1N1) (19.6%, 18/92) and adenovirus (ADV) (14.1%, 13/92), which showed significant difference with the positive rates of the three viruses in 2020 (RSV A: χ(2)=27.346, 0.01; FluA (H1N1): χ(2)=28.083, 0.01; ADV: χ(2)=7.848, 0.005) . In 2018, the positive rate of pathogens was 61.0% (50/82), with the highest rate for human bocavirus (HBoV) (13.4%, 11/82) and followed by ADV (11.0%, 9/82), and significant difference was shown in the positive rate of HBoV with that in 2020 (χ(2)=6.776, 0.009). The infection rate of 2019-nCoV is low among children in Beijing with no family clustering or no close contact, even with epidemiological history. The spectrum of pathogens of ARI in children during the research period is quite different from that in the previous years when the viral infections were dominant. MP is the highest positively detected one among the main pathogens during the outbreak of COVID-19 in Beijing where there is no main outbreak area.
调查2019年冠状病毒病(COVID-19)疫情期间小儿急性呼吸道感染(ARI)患者的病原体谱。2020年1月20日至2月20日,从首都儿科研究所招募了三组儿童进行前瞻性研究,包括有ARI且有与COVID-19相关流行病学史的暴露组儿童,采集其咽拭子和鼻咽拭子;无COVID-19相关流行病学史的ARI组儿童;以及既无COVID-19相关流行病学史也无ARI的入院筛查组儿童。ARI组和筛查组仅采集鼻咽拭子。每组预计至少纳入30例。所有标本使用来自不同厂家的两种诊断试剂盒检测2019-nCoV核酸。所有鼻咽拭子检测多种呼吸道病原体,同时将ARI组的结果与2019年和2018年同期的结果进行比较,采用或χ(2)检验。共244名儿童纳入三组,其中男性139名,女性105名,年龄为(5±4)岁。所有儿童2019-nCoV核酸检测均为阴性,暴露组(69.4%,25/36)和ARI组(55.3%,73/132)病原体检测阳性率较高,肺炎支原体(MP)阳性率最高(分别为19.4%,7/36和17.4%,23/132),其次是人偏肺病毒(hMPV)(分别为16.7%,6/36和9.8%,13/132)。筛查组病原体阳性率较低(11.8%,9/76)。2019年同期病原体阳性率为83.7%(77/92),呼吸道合胞病毒A(RSV A)阳性率最高(29.3%,27/92),其次是甲型流感病毒(Flu)A(H1N1)(19.6%,18/92)和腺病毒(ADV)(14.1%,13/92),与2020年这三种病毒的阳性率有显著差异(RSV A:χ(2)=27.346,P<0.01;FluA (H1N1):χ(2)=28.083,P<0.01;ADV:χ(2)=7.848,P<0.005)。2018年病原体阳性率为61.0%(50/82),人博卡病毒(HBoV)阳性率最高(13.4%,11/82),其次是ADV(11.0%,9/82),HBoV阳性率与2020年有显著差异(χ(2)=6.776,P<0.009)。在北京无家庭聚集或无密切接触、即使有流行病学史的儿童中,2019-nCoV感染率较低。研究期间儿童ARI的病原体谱与前几年以病毒感染为主时大不相同。在北京无主要疫情地区的COVID-19疫情期间,MP是主要病原体中检测阳性率最高的。